phenothiazine-10-carboxylic acid methyl ester | 68825-31-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻嗪类
• 英文名称: phenothiazine-10-carboxylic acid methyl ester
• 英文别名: Phenothiazin-10-carbonsaeure-methylester；N-methoxycarbonyl-phenothiazine；methyl 10H-phenothiazine-10-carboxylate；methyl phenothiazine-10-carboxylate
• CAS: 68825-31-0
• 化学式: C₁₄H₁₁NO₂S
• 分子量: 257.313
• InChiKey: WWHYODNLUNCVDI-UHFFFAOYSA-N

物化性质

• 熔点：
  148-150 °C
• 沸点：
  398.0±12.0 °C(Predicted)
• 密度：
  1.324±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  18
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  54.8
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  phenothiazine-10-carboxylic acid methyl ester 在 氯磺酸 、 sodium chloride 作用下， 以 二氯甲烷 、 水 为溶剂， 以65%的产率得到N-methoxycarbonyl-phenothiazine-2-sulfonic acid sodium salt
  参考文献：
  名称：

  Process for the direct and regioselective functionalization in position

  摘要：

  一种用于对苯并噻嗪进行直接和区域选择性官能化的方法，可以在位置2引入一个SH基团，该方法包括对用烷氧羰基、烷基磺酰基或芳基磺酰基保护的苯并噻嗪进行磺化或磺化反应，将所得产物还原以得到保护的2-巯基苯并噻嗪，然后对氮原子进行去保护。因此得到的2-巯基苯并噻嗪是制备药理活性化合物的重要中间体。

  公开号：

  US05362871A1
• 作为产物：
  描述：

  甲醇 、 吩噻嗪-10-碳酰氯 在 三乙胺 作用下， 生成 phenothiazine-10-carboxylic acid methyl ester
  参考文献：
  名称：

  具有对乙酰胆碱酯酶和丁酰胆碱酯酶具有不同抑制机制的氨基甲酸酯。

  摘要：

  大多数氨基甲酸酯是胆碱酯酶的假不可逆抑制剂。吩噻嗪氨基甲酸酯显示出对乙酰胆碱酯酶的这种抑制作用，但产生了对丁酰胆碱酯酶的可逆抑制作用，表明它们未与催化丝氨酸形成共价键。这种非典型的抑制作用归因于吩噻嗪部分与丁酰胆碱酯酶中的F329和Y332进行pi-pi相互作用。这些残基在一个螺旋段中，此处称为E-螺旋，因为它包含催化三联体的E325。使用该酶在A328，F329或Y332处的突变体可证实典型的拟不可逆抑制作用，从而证实了E-螺旋参与了吩噻嗪氨基甲酸酯对丁酰胆碱酯酶的可逆抑制。因此，除了丁酰胆碱酯酶活性位点的各个结构域之外，

  DOI：

  10.1021/jm8002075

文献信息

• Dahlbom, Acta Chemica Scandinavica (1947), 1953, vol. 7, p. 885,887
  作者：Dahlbom

  DOI：——

  日期：——
• Process for the direct and regioselective functionalization in position 2 of phenothiazine
  申请人：ZAMBON GROUP S.p.A.

  公开号：EP0499126B1

  公开（公告）日：1997-08-20
• RECHARGEABLE METAL OR METAL-ION CELL
  申请人：Solvay SA

  公开号：EP2641288B1

  公开（公告）日：2016-08-17
• Inhibitors of Cyclic Nucleotide Synthesis and Their Use for Therapy of Various Diseases
  申请人：Guerrant Richard L.

  公开号：US20100035867A1

  公开（公告）日：2010-02-11

  We disclose a method of inhibiting activity of adenylyl cyclase or guanylyl cyclase in a mammal by administering to the mammal an amount of a composition effective to inhibit the activity, wherein the composition contains at least one compound selected from the group consisting of structural formulae (Ia) and (Ib) and salts thereof, wherein R1 is —H or has the structure —C(═O)R8; R2 is ═O or has the structure —OC(═O)R9; and R3, R4, R5, R6, and R7 are each independently selected from the group consisting of —H, —NO 2 , formula (I), -halogen, —OC(═O)R9, —OR9, —OH, —R8OH, —CH 3 , —OC(═O)CH 2 Ph, formulae (II), (III), (IV), —OPh, —CF 3 , —R8, —C(═O)OR9, -Ph, —R8Ph, formulae (V), (VI), (VII), (VIII), (IX), (X), (XI), (XII), (XIII), (XIV), (XV), (XVI), (XVII), (XVIII), (XIX), (XX), and (XXI), wherein each R8 is independently a linear or branched hydrocarbon group having from 1 to 4 carbon atoms and each R9 is independently a hydrocarbon group having from 1 to 2 carbon atoms. Administering the composition can be used to treat a disease in a mammal mediated by activity of adenylyl cyclase or guanylyl cyclase and effected by a toxin produced by a pathogenic organism or to reduce cyclic AMP or cyclic GMP levels in a mammal in need of reduction thereof. The composition can also be administered to mammalian cells in vitro. The above methods of inhibiting activity of adenylyl cyclase or guanylyl cyclase and treating diseases via such inhibition can be effective without prolonged treatment, have reversible effects, have low or no toxicity, are highly potent, are unlikely to have side effects, do not act on purinergic receptors, or can negate pathogenic toxins independently of whether the pathogenic organism survives.
• Rechargeable metal or metal-ion cell
  申请人：Deronzier Alain

  公开号：US20130230771A1

  公开（公告）日：2013-09-05

  A rechargeable metal ion cell comprising: an anode comprising at least one metal; a charge-carrying electrolyte comprising a charge carrying medium and at least one metal salt; and an organic polymer cathode, wherein such cathode comprises at least one N-substituted polyphenothiazine polymer [polymer (P)], such polymer (P) comprising at least one N-substituted phenothiazine recurring unit of formula: wherein R′ is an electron-withdrawing group comprising at least one heteroatom selected from the group consisting of O, S, P, and N.